Elan Drug Technologies, the world?s leading drug delivery business, delivers clinically meaningful benefits to patients by using our extensive experience and proprietary delivery technologies in partnership with pharmaceutical companies to develop new and innovative products.
Elan Drug Technologies, the world’s leading drug delivery business, delivers clinically meaningful benefits to patients by using our extensive experience and proprietary delivery technologies in partnership with pharmaceutical companies to develop new and innovative products. With over 40 years experience in the drug delivery business, we have successfully brought 36 drugs to market for clients in over 100 markets. We have successful collaborations with the majority of the world’s leading pharma companies with client annual in-market sales of over $3 billion.
Drug optimization, development and manufacture
Elan has a unique platform of technologies to offer our clients - from oral controlled release, delayed release, pulsatile release delivery systems to technology solutions for poorly water soluble compounds. We have a complete range of capabilities from formulation development through to commercial scale manufacture in modern facilities. Our technologies are supported by a robust patent estate of over 1,900 patents / patent applications. Elan has developed unique capabilities to from early stage development right through to full scale final dosage form manufacture.
INVITATION TO MEET WITH US
Join us at CPhI Worldwide Annual meeting from October 5-7 in Paris where we will at booth location 5D63. To organise a meeting e-mail us at edtqueries@elan.com or check out our website to see the range of services we offer.
www.elandrugtechnologies.com
Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries
May 30th 2025In this podcast episode, we discuss novel approaches to drug delivery, specifically regarding adeno-associated virus (AAV) vectors, as viewed by two industry experts who recently exhibited at the annual ASGCT meeting.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Hesperos, Psilera Agree to Accelerate Organ-on-a-Chip Treatment for Frontotemporal Dementia
June 9th 2025The partnership leverages the Hesperos organ-on-a-chip platform in the preclinical development of Psilera’s lead compound targeting the progressive neurological disorder for which treatment options are few.